

1 **Analysis and validation of a highly sensitive one-step nested quantitative**  
2 **real-time polymerase chain reaction assay for specific detection of severe acute**  
3 **respiratory syndrome coronavirus 2**

4 Yang Zhang<sup>1#</sup>, Chunyang Dai<sup>1#</sup>, Huiyan Wang<sup>1</sup>, Yong Gao<sup>2</sup>, Tuantuan Li<sup>2</sup>, Yan Fang<sup>2</sup>,  
5 Zuojun Shen<sup>1</sup>, Lichang Chen<sup>2</sup>, Zhaowu Chen<sup>1</sup>, Xuejun Ma<sup>3,4\*</sup>, Ming Li<sup>1\*</sup>

6 <sup>1</sup>Department of Clinical Laboratory, The First Affiliated Hospital of University of  
7 Science and Technology of China, Hefei 230031, China.

8 <sup>2</sup>Department of Clinical Laboratory, Fuyang Second People's Hospital, Fuyang  
9 Infectious Disease Clinical College, Anhui Medical University, Fuyang 236015,  
10 China.

11 <sup>3</sup>National Institute for Viral Disease Control and Prevention, Chinese Center for  
12 Disease Control and Prevention, Beijing 102206, China.

13 <sup>4</sup>Center for Biosafety Mega-Science, Chinese Academy of Sciences, Wuhan 430071,  
14 China;

15 #YangZhang and ChunyangDai contributed equally to this article.

16

17 \*Corresponding author:

18 Ming Li, Department of Clinical Laboratory, The First Affiliated Hospital of  
19 University of Science and Technology of China, Hefei 230031, China.  
20 E-mail:liming19831002@163.com.

21 Xuejun Ma, National Institute for Viral Disease Control and Prevention, Chinese  
22 Center for Disease Control and Prevention, Beijing 102206, China. Center for  
23 Biosafety Mega-Science, Chinese Academy of Sciences, Wuhan 430071, China;

24 E-mail:maxj@ivdc.chinacdc.cn

25

## 26 **ABSTRACT**

27 Coronavirus disease 2019 (COVID-19), caused by SARS-CoV-2, is posing a serious  
28 threat to global public health. Reverse transcriptase real-time quantitative polymerase  
29 chain reaction (qRT-PCR) is widely used as the gold standard for clinical detection of  
30 SARS-CoV-2. Due to technical limitations, the reported positive rates of qRT-PCR  
31 assay of throat swab samples vary from 30%–60%. Therefore, the evaluation of  
32 alternative strategies to overcome the limitations of qRT-PCR is required. A previous  
33 study reported that one-step nested (OSN)-qRT-PCR revealed better suitability for  
34 detecting SARS-CoV-2. However, information on the analytical performance of  
35 OSN-qRT-PCR is insufficient. In this study, we aimed to analyze OSN-qRT-PCR by  
36 comparing it with droplet digital PCR (ddPCR) and qRT-PCR by using a dilution  
37 series of SARS-CoV-2 pseudoviral RNA and a quality assessment panel. The clinical  
38 performance of OSN-qRT-PCR was also validated and compared with ddPCR and  
39 qRT-PCR using specimens from COVID-19 patients. The LoD (copies/ml) of  
40 qRT-PCR, ddPCR, and OSN-qRT-PCR were 520.1 (95% CI: 363.23–1145.69) for  
41 ORF1ab and 528.1 (95% CI: 347.7–1248.7) for N, 401.8 (95% CI: 284.8–938.3) for  
42 ORF1ab and 336.8 (95% CI: 244.6–792.5) for N, and 194.74 (95% CI: 139.7–430.9)  
43 for ORF1ab and 189.1 (95% CI: 130.9–433.9) for N, respectively. Of the 34 clinical  
44 samples from COVID-19 patients, the positive rates of OSN-qRT-PCR, ddPCR, and  
45 qRT-PCR were 82.35% (28/34), 67.65% (23/34), and 58.82% (20/34), respectively. In  
46 conclusion, the highly sensitive and specific OSN-qRT-PCR assay is superior to  
47 ddPCR and qRT-PCR assays, showing great potential as a technique for detection of  
48 SARS-CoV-2 in patients with low viral loads.

49 **Keywords:** COVID-19, SARS-CoV-2, qRT-PCR, OSN-qRT-PCR, ddPCR, highly  
50 sensitive

51

## 52 **INTRODUCTION**

53 The global coronavirus disease 2019 (COVID-19) pandemic, caused by infection of  
54 severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2), is posing an  
55 enormous burden on social, economic, and healthcare systems worldwide<sup>[1]</sup>. As there  
56 is currently no specific treatment option, early detection of SARS-CoV-2-infected  
57 patients has facilitated effective isolation and treatment to prevent disease spread.  
58 Currently, clinical diagnosis of COVID-19 is mainly confirmed by detecting  
59 SARS-CoV-2 RNA using reverse transcriptase real-time quantitative polymerase  
60 chain reaction (qRT-PCR)<sup>[2-5]</sup>. However, the sensitivity and reliability of qRT-PCR  
61 has been questioned due to cases of negative results in some patients who were highly  
62 suspected of having the disease based on clinical presentation and exposure history  
63 <sup>[6,7]</sup>.

64 Droplet digital PCR (ddPCR) is a third generation PCR based on the principles of  
65 limited dilution and Poisson statistics<sup>[8,9]</sup>, which works by separating a sample into  
66 thousands to millions of droplets and then partitioning them to be read as either  
67 positive or negative depending on fluorescence amplitude<sup>[10-13]</sup>. These vast and highly  
68 consistent oil droplets substantially improve the detection dynamic range and  
69 accuracy of ddPCR<sup>[14]</sup>. In recent years, ddPCR has found many applications, such as  
70 analysis of viral load from clinical samples, detection of rare mutations, analysis of  
71 copy number variation (CNV), and precise miRNA quantification<sup>[15-17]</sup>.

72 Given the high sensitivity of ddPCR, Zhao JK et al. utilized this technique to evaluate  
73 the viral loads of SARS-CoV-2 from upper respiratory tract specimens for the first  
74 time, showing that ddPCR can accurately reflect the viral loads of such specimens,  
75 especially nasopharyngeal swabs<sup>[18]</sup>. Subsequently, Renfei Lu et al. used serial  
76 dilutions of the same clinical samples to demonstrate that the LoD of ddPCR is at  
77 least 10 times better than that of qRT-PCR<sup>[19]</sup>. However, the limitation of the ddPCR  
78 assay is that it often needs unique supporting reagents, instruments, and professional  
79 operators, causing high running costs with moderate throughput. More convenient and  
80 sensitive methods are urgently needed as alternative diagnostic approaches for  
81 detecting SARS-CoV-2.

82 Nested PCR typically utilizes two sequential amplification reactions, each of which  
83 uses a different pair of primers, resulting in an increase in sensitivity and specificity.  
84 The product of the first amplification reaction is used as the template for the second,  
85 which is primed by oligonucleotides that are placed internal to the first primer pair.  
86 The use of two pairs of oligonucleotides allows for a higher number of cycles to be  
87 performed, thereby increasing the sensitivity of the PCR. Feng ZS et al. previously  
88 developed a novel locked nucleic acid (LNA)-based one-step single-tube nested  
89 (OSN)-qRT-PCR strategy to detect viral and bacterial pathogens with higher  
90 sensitivity and specificity than qRT-PCR and without the need of lid opening<sup>[20]</sup>. To  
91 improve the diagnostic accuracy of nucleic acid detection of SARS-CoV-2 in low  
92 viral load samples, they developed and evaluated the sensitivity and accuracy of  
93 OSN-qRT-PCR in detecting SARS-CoV-2<sup>[21]</sup>. However, the analytical performance of  
94 OSN-qRT-PCR in the published study is insufficient, lacking information such as  
95 specificity, reportable range, and the limit of detection (LoD). In addition, no studies  
96 have been conducted comparing the clinical application value of OSN-qRT-PCR and  
97 ddPCR for detecting SARS-CoV-2.

98 Here we provide a comparison of OSN-qRT-PCR and ddPCR with qRT-PCR using a  
99 dilution series of SARS-CoV-2 pseudoviral RNA and clinical samples. The detectable  
100 range and sensitivity of each assay were determined and clinical samples (n = 34)  
101 were used to validate clinical sensitivity and specificity. Compared with qRT-PCR and  
102 ddPCR, OSN-qRT-PCR showed higher sensitivity and greater practicality, making it  
103 better suited for detecting SARS-CoV-2 in low viral load samples.

104

## 105 **MATERIALS AND METHODS**

106 **Ethics statement.** The Ethics Committee of The Second People's Hospital of Fuyang  
107 approved this study. Existing samples collected during standard diagnostic tests were  
108 tested and analyzed by qRT-PCR, OSN-qRT-PCR, and ddPCR. No extra burden was  
109 posed to patients.

110 **Specimen collection.** We retrospectively identified 24 hospitalized patients clinically  
111 diagnosed with COVID-19 between January 30, 2020, and February 17, 2020, in The  
112 Second People's Hospital of Fuyang. Throat (n = 18) and anal (n = 4) swabs, sputum  
113 (n = 10), and blood (n = 2) samples were collected from the enrolled patients. All  
114 aspects of the study were performed according to national ethics regulations and  
115 approved by the Institutional Review Boards of China Center for Disease Control and  
116 Prevention (CDC). Written consent was obtained from patients or children's parents.

117 **SARS-CoV-2 pseudovirus preparation.** The SARS-CoV-2 reference sequence was  
118 synthesized and cloned into a lentiviral vector and pseudovirus was prepared in 293T  
119 cells. The obtained pseudovirus contained RNA sequences of the *ORF1ab* and *N*  
120 genes in the lentiviral genome. The SARS-CoV-2 pseudovirus used in qRT-PCR and  
121 OSN-qRT-PCR was synthesized and processed by BDS company (DA'an, Guangzhou,  
122 China) at a RNA concentration of  $2.0 \times 10^4$  copies/ml. The SARS-CoV-2 pseudovirus  
123 used in ddPCR was synthesized and processed by BioPerfectus Technologies Co.  
124 (Taizhou, China) at a RNA concentration of  $1.5 \times 10^5$  copies/ml. The SARS-CoV-2  
125 pseudoviral RNA was diluted with pseudovirus diluent (dilution ratio and method is  
126 shown in table 1), and SARS-CoV-2 pseudoviral RNA of the diluted samples S1, S2,  
127 S3, S4, S5, S6, S7, and S8 were extracted by using membrane adsorption kits (Di'an,  
128 Hangzhou, China).

129 **RNA extraction.** Total RNA from throat and anal swabs, sputum, and blood samples  
130 from each patient was extracted from supernatants using Reagent of Nucleic Acid  
131 Extraction or Purification (Di'an, Hangzhou, China) following the manufacturer's  
132 instructions. SARS-CoV-2 nucleic acid detection was mainly targeted at the  
133 two-segment conserved gene sequence of its genome, located at *ORF1ab* and *N*.

134 **ddPCR workflow.** Reaction components of the ddPCR assay kit (BioPerfectus)  
135 included 5  $\mu$ l of Supermix, 2  $\mu$ l of reverse transcriptase, 1  $\mu$ l of 300 mM DTT, 5  $\mu$ l of  
136 SARS-CoV-2 reaction solution, and 7  $\mu$ l template. All procedures followed the  
137 manufacturer's instructions for the QX200 Droplet Digital PCR System using

138 Supermix for the probe (no dUTP) (Bio-Rad, Hercules, USA). 20 µl of each reaction  
139 mix was converted to droplets with the QX200 droplet generator. Droplet-partitioned  
140 samples were then transferred to a 96-well plate, sealed, and cycled in a C1000 Touch  
141 Thermal Cycler (Bio-Rad) under the following cycling protocol: 50°C for 60 min and  
142 95°C for 10 min, followed by 40 cycles of 95°C for 30 s and 56°C for 1 min, then  
143 98°C for 10 min and 4°C hold. FAM (*ORF1ab*) and HEX (*N*) channels were selected  
144 to detect SARS-CoV-2. The cycled plate was then transferred and FAM and HEX  
145 channels read using the QX200 reader. Each run contained positive and negative  
146 controls. Samples were only considered positive when both FAM and HEX channels  
147 had signals.

148 **OSN-qRT-PCR workflow.** Reaction components of the OSN-qRT-PCR assay kit  
149 (Sansure, Changsha, China) included 20 µl of template, 26 µl of reaction buffer, and 4  
150 µl of the enzyme mixture. After vortexing and centrifugation, the reaction tube was  
151 transferred to the LightCycler 480 II Real-Time PCR System (Roche, Basel,  
152 Switzerland). The OSN-qRT-PCR amplification reaction contained the following  
153 steps: 50°C for 30 min, 95°C for 1 min, 20 cycles at 95°C for 30 s, 70°C for 40 s, and  
154 72°C for 40s, followed by 40 cycles at 95°C for 15 s, 60°C for 30 s, and 25°C for 10 s  
155 of instrument cooling. FAM (*ORF1ab*) and ROX (*N*) channels were selected to detect  
156 SARS-CoV-2, and the VIC channel was chosen to detect the reference gene (human  
157 *ABLI*). Each run contained positive and negative controls. FAM, HEX, and VIC  
158 channels all showed typical S-shaped amplification curves. The result was considered  
159 valid when the cycle threshold (Ct) value of the reference gene was  $\leq 37$ . The result  
160 was considered positive when the Ct values of both target genes were  $\leq 35$  and  
161 negative when they were both  $> 35$ . If only one of the target genes had a Ct value  $\leq 35$   
162 and the other was  $> 35$ , it was interpreted as a single-gene positive.

163 **qRT-PCR workflow.** The qRT-PCR kit (DaAn Gene; Guangzhou, China) included 17  
164 µl of SARS-CoV-2 NC reaction solution A, 3 µl of NC reaction solution B, and 5 µl  
165 of template. After vortexing and centrifugation, the reaction tube was transferred to  
166 the LightCycler 480 II Real-Time PCR System (Roche). The qRT-PCR amplification

167 reaction contained the following steps: 50°C for 15 min, 95°C for 15 min, 45 cycles at  
168 94°C for 15 s, and 55°C for 45 s. FAM (*N*) and VIC (*ORF1ab*) channels were selected  
169 to detect SARS-CoV-2, and the CY5 channel was chosen to detect the reference gene  
170 (human *ABL1*). The result was considered valid when the Ct value of the reference  
171 gene was  $\leq 37$ . The result was considered positive when the Ct values of both target  
172 genes (*ORF1ab* and *N*) were  $\leq 37$  and were considered negative when they were  
173 both  $> 40$ . If only one of the target genes had a Ct value fall in the gray zone (37–40),  
174 it was retested. If the repeated result was positive for only one of two targets genes, it  
175 was interpreted as positive.

176 **Dynamic range and LoD of OSN-qRT-PCR, ddPCR, and qRT-PCR.** To evaluate  
177 the dynamic range and consistency of OSN-qRT-PCR, ddPCR, and qRT-PCR, we first  
178 ran a serial dilution of the linear RNA standard for each assay. To determine the LoD,  
179 the lower concentration RNA standards (including S3–S8) were analyzed 14 times.  
180 The LoD was calculated by Probit regression analysis with a 95% repeatable  
181 probability.

182 **Data statistical analysis.** Analysis of the ddPCR data was performed with Quanta  
183 Soft Analysis Software v1.7.4 to calculate the concentration of the target. Plots of  
184 linear regression were conducted with GraphPad Prism 7.0, and Probit analysis for  
185 LoD was conducted with MedCalc software v19.2.1. Bland-Altman analysis of  
186 qRT-PCR, OSN-qRT-PCR, and ddPCR results for patient samples was evaluated by  
187 SPSS 23.0 statistical software.

188

## 189 RESULTS

190 **Comparison of the reportable range of each assay.** To compare the reportable range  
191 of qRT-PCR, OSN-qRT-PCR, and ddPCR, the SARS-CoV-2 pseudoviral RNA  
192 standard was serially diluted from  $2 \times 10^4$  to 20 copies/ml for qRT-PCR and  
193 OSN-qRT-PCR, and from  $1 \times 10^5$  to 150 copies/ml for ddPCR. As shown in figure 1,  
194 the detectable range of qRT-PCR was 500 to  $2 \times 10^4$  copies/ml for *ORF1ab* and *N*,



195 with  $R^2 = 0.9985$  and  $0.9967$ , respectively (Fig. 1a,b). The detectable range of  
196 OSN-qRT-PCR was 100 to  $2 \times 10^4$  copies/ml for *ORF1ab* and 50 to  $2 \times 10^4$  copies/ml  
197 for *N*, with  $R^2 = 0.9874$  and  $0.9936$ , respectively (Fig. 1c,d). Likewise, the detectable  
198 range of ddPCR was 250 to  $1.5 \times 10^5$  copies/ml for *ORF1ab* and *N*, with  $R^2 = 0.9983$   
199 and  $0.9984$ , respectively (Fig. 1e,f). These results show that the minimum detection  
200 range of OSN-qRT-PCR is significantly lower than those of qRT-PCR and ddPCR.  
201 Moreover, both OSN-qRT-PCR and ddPCR results displayed good linearity,  
202 suggesting that both assays can reliably detect SARS-CoV-2.

203 In addition, we compared the correlation between OSN-qRT-PCR and ddPCR with  
204 qRT-PCR and, as shown in figure 2, found that the Pearson correlation coefficients  
205 between qRT-PCR and OSN-qRT-PCR were  $0.887$  for *ORF1ab* and  $0.742$  for *N* (Fig.  
206 2a,b), and  $-0.924$  for *ORF1ab* and  $-0.844$  for *N* between qRT-PCR and ddPCR (Fig.  
207 2c,d). The good correlation between qRT-PCR with the other two assays further  
208 confirms that OSN-qRT-PCR and ddPCR are suitable methods for detecting  
209 SARS-CoV-2.

210 **Comparison of the LoD for each assay.** A variety of procedures are available for  
211 establishing the LoD for laboratory assays. The LoD is generally determined in one of  
212 two ways: either (i) statistically, by calculating the point at which a signal can be  
213 distinguished from background, or (ii) empirically, by testing serial dilutions of  
214 samples with a known concentration of the target substance in the analytical range of  
215 the expected detection limit. For medical applications of molecular assays, it is  
216 generally more meaningful to use the empirical method to estimate the detection limit.

217 The LoD was calculated by Probit regression analysis with a 95% repeatable  
218 probability, which is a commonly used method when empirically determining the  
219 limit of analyte that can be reliably detected. A series of linear SARS-CoV-2  
220 pseudoviral RNA concentrations (including S3–S8) were prepared by diluting a  
221 high-concentration standard, with each concentration tested with 14 replicates. As  
222 shown in figure 3 and table 2, the LoD of qRT-PCR was 520.1 (95% confidence



223 interval (CI): 363.23–1145.69) and 528.1 (95% CI: 347.7–1248.7) copies/ml for  
224 *ORF1ab* and *N*, respectively (Fig. 3a,b). The qRT-PCR kit claims a detection  
225 sensitivity of 500 copies/ml and was officially approved by the National Medical  
226 Products Administration (NMPA) and used for the detection of COVID-19 nationwide.  
227 Our LoD result was consistent with this claimed detection limit.

228 In contrast, the LoD of OSN-qRT-PCR was 194.74 (95% CI: 139.7–430.9) and 189.1  
229 (95% CI: 130.9–433.9) copies/ml for *ORF1ab* and *N*, respectively (Fig. 3c,d), while  
230 the LoD of ddPCR was 401.8 (95% CI: 284.8–938.3) and 336.8 (95% CI: 244.6–  
231 792.5) copies/ml for *ORF1ab* and *N*, respectively (Fig. 3e,f). Taken together, these  
232 results show that the sensitivity of OSN-qRT-PCR is higher than both ddPCR and  
233 qRT-PCR, with ddPCR being more sensitive than qRT-PCR.

234 **Comparison of repeatability and conformity using intra-assay and**  
235 **inter-laboratory quality assessment panels.** A series of linear SARS-CoV-2  
236 pseudoviral RNA concentrations (including S0–S6) were tested in triplicates within  
237 the same run. As shown in table 3, the coefficient of variation (CV) values of  
238 intra-assays ranged from 1.60%–5.92% for qRT-PCR, 1.47%–4.99% for  
239 OSN-qRT-PCR, and 2.04%–11.18% for ddPCR. Overall, these results show that  
240 qRT-PCR and OSN-qRT-PCR assays demonstrate good repeatability. The cause of the  
241 unstable ddPCR results may be a consequence of differences in the number of  
242 microspheres due to poor machine operation by the experimenter.

243 The inter-laboratory quality assessment panel provided by the National Center for  
244 Clinical Laboratories (NCCL) is used for evaluation of a laboratory's ability to detect  
245 nucleic acids of SARS-CoV-2. This panel includes a total of 10 samples named as  
246 202001–202010. As shown in table 4, the test results of each assay using this panel  
247 indicate that both OSN-qRT-PCR and ddPCR assays showed 100% specificity for  
248 detecting SARS-CoV-2 and were negative for other human coronaviruses.

249 **Comparison of each assay for SARS-CoV-2 RNA detection using patient samples**  
250 **in the acute phase of infection.** A total of 34 samples from 24 COVID-19-confirmed

251 patients diagnosed in the acute phase of infection were analyzed by each assay. The  
252 positive threshold for SARS-CoV-2 detection was defined as values equal to or  
253 greater than the LoD of *ORF1ab* and *N* primers/probe sets. The results of qRT-PCR,  
254 OSN-qRT-PCR, and ddPCR for each sample are shown in tables 5 and 6. Among the  
255 34 samples, 14 samples were initially qRT-PCR negative (positive rate = 58.82%),  
256 while 28 tested positive by OSN-qRT-PCR (positive rate = 82.35%). In addition, 23  
257 tested positive by ddPCR (positive rate = 67.65%), indicating a higher sensitivity than  
258 qRT-PCR but lower than OSN-qRT-PCR. These results were further analyzed by the  
259 Bland–Altman method, which reveals the agreement between two independent  
260 methods. As shown in figure 4, OSN-qRT-PCR and ddPCR results were in good  
261 agreement with qRT-PCR. Therefore, both OSN-qRT-PCR and ddPCR assays proved  
262 capable of detecting SARS-CoV-2 in patient specimens.

263 **Comparison of the positive rates of different specimen types from COVID-19**  
264 **patients.** A previous study revealed that SARS-CoV-2 exists in both the upper and  
265 lower respiratory tract<sup>[22]</sup>. We collected simultaneous sputum and throat swabs from a  
266 total of 10 COVID-19-confirmed patients diagnosed in the acute phase of infection  
267 and the three methods were used to detect SARS-CoV-2 nucleic acid. As shown in  
268 table 7, the positive rates in sputum samples for all three methods were significantly  
269 higher than those of throat swabs. In addition, we also collected blood specimens (n =  
270 2) and anal swab specimens (n = 4) from COVID-19-confirmed patients to analyze  
271 the detection ability of the assays for other specimen types. As shown in table 4, for  
272 blood specimens (29<sup>#</sup> and 30<sup>#</sup>), qRT-PCR and ddPCR results were both negative,  
273 while the OSN-qRT-PCR result was positive. For anal swab specimens (31<sup>#</sup>–34<sup>#</sup>),  
274 only one case was positive by ddPCR and qRT-PCR assay, while all four were  
275 positive by OSN-qRT-PCR. It is evident from these results that among the three  
276 methods, OSN-qRT-PCR has the greatest sensitivity for detecting SARS-CoV-2 from  
277 different specimen types.

278

## 279 DISCUSSION

280 The clinical detection sensitivity of qRT-PCR is affected by various factors, such as  
281 the nucleic acid extraction method, the one-step qRT-PCR reagent used, and the  
282 primer/probe sets<sup>[23]</sup>. It has been reported that seven commercial qRT-PCR detection  
283 kits revealed significant differences in the detection ability for weakly positive  
284 samples<sup>[24]</sup>. ddPCR has exhibited higher sensitivity and precision than classical  
285 qRT-PCR<sup>[25,26]</sup>. Recent studies have confirmed that both ddPCR and OSN-qRT-PCR  
286 are strongly recommended in clinical practice for the diagnosis of COVID-19 and for  
287 follow-up of positive patients until complete remission<sup>[21,27]</sup>. However, ddPCR is  
288 limited to special equipment, which hinders its clinical application. Compared with  
289 ddPCR, the advantage of OSN-qRT-PCR is greater practicality because of easier  
290 adaptation for laboratories already equipped with traditional real-time PCR machines.

291 Here, for the first time, we provide a head-to-head comparison of OSN-qRT-PCR and  
292 ddPCR with qRT-PCR for the detection of SARS-CoV-2 using a pseudoviral RNA  
293 standard, inter-laboratory quality assessment panel, and clinical samples of different  
294 types. The detectable range, consistency, specificity, and LoD of each method were  
295 comparably analyzed. Our results demonstrate that OSN-qRT-PCR and ddPCR are  
296 reliable for quantitatively detecting SARS-CoV-2. In addition, Bland–Altman analysis  
297 showed that ddPCR and OSN-qRT-PCR had good correlation with qRT-PCR in  
298 testing clinical specimens. In particular, the detection performance of both  
299 OSN-qRT-PCR and ddPCR assays were better than qRT-PCR, and the OSN-qRT-PCR  
300 assay had the lowest LoD, suggesting that OSN-qRT-PCR and ddPCR assays are  
301 valuable additions for detecting SARS-COV-2 in samples with low viral loads.  
302 Although the sensitivity of OSN-qRT-PCR was reported to be 10-fold higher than  
303 qRT-PCR using plasmids<sup>[21]</sup>, our results revealed that the sensitivity of  
304 OSN-qRT-PCR was only 2–3-fold higher than qRT-PCR when using pseudoviral  
305 RNA.

306 A previous study revealed that SARS-CoV-2 exists in both the upper and lower

307 respiratory tract and that the viral load in sputum is higher than that of throat swabs  
308 [28]. Our findings also confirmed that although SARS-CoV-2 can colonize the upper  
309 respiratory tract, lower respiratory tract samples better reflect the viral replication  
310 level in infected patients. Although OSN-qRT-PCR and ddPCR both exhibited higher  
311 sensitivity than qRT-PCR, there were still false negative results (six missed by  
312 OSN-qRT-PCR, 11 missed by ddPCR) when analyzing clinical specimens. This may  
313 have been due to the quality of sample collection or viral loads falling below detection  
314 limits resulting from missing the optimum sample collection time. For specimen 20<sup>#</sup>,  
315 the results of OSN-qRT-PCR and qRT-PCR were negative, while ddPCR was positive.  
316 This discordant result may have been due to the specimen type (sputum) or the various  
317 influencing factors in the nucleic acid extraction process, leading to poor stability of  
318 test results.

319 This study had several limitations. First, the SARS-CoV-2 pseudoviral RNA  
320 concentration used in the study for exploring detectable ranges did not include high  
321 concentrations. Second, the clinical specimens were only from COVID-19-confirmed  
322 patients in the acute phase of infection; clinical specimens from patients in the  
323 recovery phase or suspected patients were not included. Finally, our study was limited  
324 by a small sample size and thus conclusions should be interpreted with caution and  
325 confirmed by further studies.

326

## 327 **CONCLUSION**

328 We validated the implementation of OSN-qRT-PCR and ddPCR systems as new  
329 alternatives to qRT-PCR for the sensitive and accurate quantification of SARS-CoV-2,  
330 especially in samples with low viral loads. Considering its sensitivity and practicality,  
331 OSN-qRT-PCR is a highly valuable and feasible method that offers the potential to  
332 facilitate clinical diagnoses and decision-making for patients with COVID-19.

333

334 **CONFLICTS OF INTEREST**

335 The authors declare no conflicts of interests.

336 **FUNDING**

337 This study was supported by the New Coronavirus Infection Emergency Science and  
338 Technology Project, Clinical Research Hospital of Chinese Academy of  
339 Sciences[grant number YD9110002010], the Fundamental Research Funds for the  
340 Central University [grant number WK9110000025], the Natural Science Foundation  
341 of Anhui Province (Grant Number: 2008085MH288), the China Mega-Projects for  
342 Infectious Disease (2017ZX10104001, 2018ZX10711001, and 2018ZX10713-002).

343

344 **REFERENCE**

345 [1]World Health Organization (WHO), COVID-19. [https://www.who.int/emergencies/](https://www.who.int/emergencies/diseases/novel-coronavirus-2019)  
346 [diseases/novel-coronavirus-2019](https://www.who.int/emergencies/diseases/novel-coronavirus-2019), 2020 (accessed 8 April 2020).

347 [2]V.M. Corman, O. Landt, M. Kaiser, R. Molenkamp, A. Meijer, D.K.W. Chu, T. Bleicker, S.  
348 Brünink, J. Schneider, M.L. Schmidt, D.G.J.C. Mulders, B.L. Haagmans, B. van der Veer, S. van  
349 den Brink, L. Wijsman, G. Goderski, J.L. Romette, J. Ellis, M. Zambon, M. Peiris, H. Goossens, C.  
350 Reusken, M.P.G. Koopmans, C. Drosten, Detection of 2019 novel coronavirus (2019-nCoV) by  
351 real-time RT-PCR, *Euro. Surveill.* 25 (2020).

352 [3]K. Shirato, N. Nao, H. Katano, I. Takayama, S. Saito, F. Kato, H. Katoh, M. Sakata, Y. Nakatsu,  
353 Y. Mori, T. Kageyama, S. Matsuyama, M. Takeda, Development of Genetic Diagnostic Methods  
354 for Novel Coronavirus 2019 (nCoV-2019) in Japan, *Jpn. J. Infect. Dis.* (2020).

355 [4]R. Konrad, U. Eberle, A. Dangel, B. Treis, A. Berger, K. Bengs, V. Fingerle, B. Liebl, N.  
356 Ackermann, A. Sing, Rapid establishment of laboratory diagnostics for the novel coronavirus  
357 SARS-CoV-2 in Bavaria, Germany, February 2020, *Euro. Surveill.* 25 (2020).

358 [5]D.K.W. Chu, Y. Pan, S.M.S. Cheng, K.P.Y. Hui, P. Krishnan, Y. Liu, D.Y.M. Ng, C.K.C. Wan, P.  
359 Yang, Q. Wang, M. Peiris, L.L.M. Poon, Molecular Diagnosis of a Novel Coronavirus  
360 (2019-nCoV) Causing an Outbreak of Pneumonia, *Clin. Chem.* 66 (2020) 549–555.

361 [6]Winichakoon, P.; Chaiwarith, R.; Liwsrisakun, C.; Salee, P.; Goonna, A.; Limsukon, A.;  
362 Kaewpoowat, Q., Negative Nasopharyngeal and Oropharyngeal Swab Does Not Rule Out

- 363 COVID-19. *J Clin Microbiol* 2020.
- 364 [7]Wu J, Liu J, Zhao X, et al. Clinical characteristics of imported cases of COVID-19 in Jiangsu  
365 Province: a multicenter descriptive study. *Clin Infect Dis* 2020. doi:10.1093/cid/ciaa199.
- 366 [8]Vogelstein B, Kinzler KW. Digital PCR. *Proc. Natl. Acad. Sci. U. S. A.* 1999;96:9236–9241.
- 367 [9]Nyarubaba, R.; Mwaliko, C.; Kering, K.K.; Wei, H. Droplet digital PCR applications in the  
368 tuberculosis world. *Tuberculosis* 2019, 117, 85–92.
- 369 [10]Green M R , Sambrook J . Nested Polymerase Chain Reaction (PCR)[J]. *Cold Spring Harbor*  
370 *Protocols*, 2019, 2019(2).
- 371 [11]Pohl G, Shih I-M. Principle and applications of digital PCR. *Expert Rev. Mol. Diagn.*  
372 2004;4:41–47.
- 373 [12]Sanders R, Mason DJ, Foy CA, et al. Evaluation of Digital PCR for Absolute RNA  
374 Quantification. *PLoS One*. 2013;8:e75296.
- 375 [13]White RA, Blainey PC, Fan HC, et al. Digital PCR provides sensitive and absolute calibration  
376 for high throughput sequencing. *BMC Genomics*. 2009;10:110–116.
- 377 [14]Hindson CM, Chevillet JR, Briggs HA, et al. Absolute quantification by droplet digital PCR  
378 versus analog real-time PCR. *Nat. Methods*. 2013;10:1003–1005.
- 379 [15]Brunetto GS, Massoud R, Leibovitch EC, et al. Digital droplet PCR (ddPCR) for the precise  
380 quantification of human T-lymphotropic virus 1 proviral loads in peripheral blood and  
381 cerebrospinal fluid of HAM/TSP patients and identification of viral mutations. *J. Neurovirol.*  
382 2014;20:341–351.
- 383 [16]Caviglia GP, Abate ML, Tandoi F, et al. Quantitation of HBV cccDNA in anti-HBc-positive  
384 liver donors by droplet digital PCR: A new tool to detect occult infection. *J. Hepatol.* [Internet].  
385 2018;69:301–307. Available from: <https://doi.org/10.1016/j.jhep.2018.03.021>.
- 386 [17]Postel M, Roosen A, Laurent-Puig P, et al. Droplet-based digital PCR and next generation  
387 sequencing for monitoring circulating tumor DNA: a cancer diagnostic perspective. *Expert Rev.*  
388 *Mol. Diagn.* 2018;18:7–17.
- 389 [18]Zhao, Jiankang & Li, Haibo & Li, Hui & Wu, Qiaoling & Wu, Ke & Xiong, Zhujia & Yu,  
390 Zhongguang & Zhu, Yue & Fan, Yanyan & Li, Binbin & Ye, Yufei & Lu, Binghuai & Cao, Bin.  
391 (2020). Viral load in upper respiratory tract of COVID-19 patients detected by digital PCR.  
392 10.21203/rs.3.rs-29834/v1.
- 393 [19]Lu R, Wang J, Li M, Wang Y, Dong J, Cai W. SARS-CoV-2 detection using digital PCR for

394 COVID-19 diagnosis, treatment monitoring and criteria for discharge. medRxiv preprint.  
395 2020; Available from: <https://doi.org/10.1101/2020.03.24.20042689>.

396 [20]Feng Z S , Zhao L , Wang J , et al. A multiplex one-tube nested real time RT-PCR assay for  
397 simultaneous detection of respiratory syncytial virus, human rhinovirus and human  
398 metapneumovirus[J]. Virology Journal, 2018, 15(1).

399 [21]Ji W, Kun C, Ruiqing Z et al. A novel one-step single-tube nested quantitative Real-Time PCR  
400 assay for highly sensitive detection of SARS-CoV-2[J]. Anal Chem,  
401 DOI:10.1021/acs.analchem.0c01884

402 [22]Chan JF, Yuan S, Kok KH, et al. A familial cluster of pneumonia associated with the 2019  
403 novel coronavirus indicating person-to-person transmission: a study of a family cluster. Lancet  
404 2020; 395:514–23.

405 [23]Xie, X.; Zhong, Z.; Zhao, W.; Zheng, C.; Wang, F.; Liu, J., Chest CT for Typical 2019-nCoV  
406 Pneumonia: Relationship to Negative RT-PCR Testing. Radiology 2020, 200343.

407 [24]Kasteren P B V , Veer B V D , Brink S V D , et al. Comparison of seven commercial RT-PCR  
408 diagnostic kits for COVID-19[J]. Journal of Clinical Virology, 2020.

409 [25]Strain MC, Lada SM, Luong T, Rought SE, Gianella S, Terry VH, et al. Highly Precise  
410 Measurement of HIV DNA by Droplet Digital PCR. Wu Y, éditeur. PLoS ONE.  
411 2013;8(4):e55943.

412 [26]Huang J-T, Liu Y-J, Wang J, Xu Z-G, Yang Y, Shen F, et al. Next Generation Digital PCR  
413 Measurement of Hepatitis B Virus Copy Number in Formalin-Fixed Paraffin-Embedded  
414 Hepatocellular Carcinoma Tissue. Clinical Chemistry. 1 janv 2015;61(1):290-6.

415 [27]Falzone L , Musso N , Gattuso G , et al. Sensitivity assessment of droplet digital PCR for  
416 SARS-CoV-2 detection[J]. International Journal of Molecular Medicine, 2020.

417 [28]Pan Y, Zhang D, Yang P, Poon LLM, Wang Q. Viral load of SARS-CoV-2 in clinical samples.  
418 Lancet Infect Dis 2020; 20:411–2.

419

420

## 421 **Tables and figures**

422 **TABLE 1 Dilution ratio and the concentration (copies/ml) of SARS-CoV-2**  
423 **pseudovirus RNA standards used in each assay**

---

qRT-PCR and OSN-qRT-PCR	ddPCR
-------------------------	-------

---



	Dilution ratio	Concentration (copies/ml)	Dilution ratio	Concentration (copies/ml)
S0	0	20000	0	150000
S1	5	4000	5	30000
S2	10	2000	20	7500
S3	20	1000	100	1500
S4	40	500	300	500
S5	100	200	600	250
S6	200	100	1000	150
S7	400	50	/	/
S8	1000	20	/	/

424

425 **TABLE 2 Estimated limit of detection for SARS-COV-2 in copies/ml for each**  
 426 **assay.**

Methods	LoD determined in assays (copies/ml)	
	<i>ORFlab</i>	<i>N</i>
qRT-PCR	520.1(95% CI: 363.23-1145.69)	528.1(95% CI: 347.7~1248.7)
OSN-qRT-PCR	194.74(95% CI: 139.7-430.9)	189.1(95% CI: 130.9-433.9)
ddPCR	401.8(95% CI: 284.8-938.3)	336.8(95% CI: 244.6-792.5)

427

428 **TABLE 3 Comparison of the repeatability (CV%) of the each assay**

Method	Conc.(copies/ml)	<i>ORFlab</i>			<i>N</i>		
		SD	MEAN	CV (%)	SD	MEAN	CV (%)
qRT-PCR	20000	0.61	30.69	1.99%	1.05	29.02	3.61%
	4000	1.36	33.22	4.09%	1.81	31.92	5.67%
	2000	0.93	34.52	2.70%	0.96	33.06	2.91%
	1000	1.55	35.76	4.32%	2.02	34.07	5.92%

	500	0.58	36.30	1.60%	1.86	36.00	5.16%
	200	0.84	37.99	2.20%	1.69	37.08	4.56%
OSN-qRT-PCR	20000	0.49	13.87	3.57%	0.09	19.21	0.47%
	4000	0.83	16.65	4.97%	0.13	22.19	0.61%
	2000	1.35	18.85	7.15%	0.38	23.68	1.62%
	1000	0.46	19.33	2.36%	0.50	24.23	2.06%
	500	0.56	20.56	2.71%	0.97	25.09	3.86%
	200	0.32	21.81	1.47%	1.31	26.30	4.99%
ddPCR	143000	5644.4	107327.3	5.26%	2862.1	86757.2	3.30%
	33000	1999.9	28569.7	7.00%	1902.0	22665.4	8.39%
	8000	458.7	9189.7	4.99%	164.9	8094.9	2.04%
	2000	75.8	2085.0	3.63%	340.8	4009.4	8.50%
	500	51.2	671.7	7.62%	62.3	557.1	11.18%
	250	22.4	261.7	8.55%	37.8	371.4	10.18%

429

430 **TABLE 4 Comparison of test results and return results of inter-laboratory**  
 431 **quality assessment panel.**

Sample ID	Test Results						Return Results	
	qRT-PCR (Ct Value)		OSN-qRT-PCR (Ct Value)		ddPCR (copies/mL)		SARS-COV-2	Pass Rate (%)
	<i>ORF-1ab</i>	<i>N</i>	<i>ORF-1ab</i>	<i>N</i>	<i>ORF-1ab</i>	<i>N</i>		
202001	—	—	—	—	—	—	negative	99
202002	31.79	30.49	16.45	20.97	3074	2073	positive	98
202003	25.99	24.23	13.78	18.68	23080	5005	positive	99
202004	33.87	32.31	20.94	21.19	1144	2860	positive	98
202005	29.93	28.87	15.56	19.53	7293	2072	positive	99
202006	—	—	—	—	—	—	negative	99
202007	32.85	31.73	18.38	20.80	1144	1573	positive	98
202008	—	—	—	—	—	—	negative	99
202009	34.85	33.91	18.92	22.43	1312	643	positive	97
202010	27.79	26.40	12.22	15.89	33962	11072	positive	99

432

433 **TABLE 5 The results of qRT-PCR, OSN-qRT-PCR and ddPCR and further**  
 434 **clinical information of 34 clinical samples from 24 acute phase COVID-19**  
 435 **patients.**

Sample ID.	Results of qRT-PCR (Ct Value)		Results of OSN-qRT-PCR(Ct Value)		Results of ddPCR (copies/ml)		Specimen type	Initial official reports by OSN-qRT-PCR	Judgm ent by N-PCR	Judgme nt by ddPCR
	<i>ORF1ab</i>	<i>N</i>	<i>ORF1ab</i>	<i>N</i>	<i>ORF1ab</i>	<i>N</i>				
	1	27.20	26.94	15.00	16.68	129415				
2	35.04	35.35	22.60	22.80	428.90	572.00	Throat swab	P	P	P
3	—	—	37.11	37.22	—	—	Throat swab	N	N	N
4	34.46	34.95	21.74	22.76	500.50	715.00	Throat swab	P	P	P
5	31.31	30.66	17.39	19.21	5148.00	10224.50	Throat swab	P	P	P
6	28.02	27.38	14.65	15.25	74360.0	364.45	Throat swab	P	P	P
7	—	—	38.21	—	—	—	Throat swab	N	N	N
8	32.61	32.70	18.17	19.96	2860.00	3503.50	Throat swab	P	P	P
9 <sup>a</sup>	40.32	—	23.50	24.64	228.80	429.00	Throat swab	N	P	S
10	35.50	35.10	23.40	23.96	715.00	715.00	Throat swab	P	P	P
11	35.08	33.09	23.60	22.14	715.00	2145.00	Throat swab	P	P	P
12	26.58	26.76	12.52	13.95	215930	4336.0	Throat swab	P	P	P
13 <sup>a</sup>	40.83	—	28.75	26.19	157.30	228.80	Throat swab	N	P	N
14	34.00	33.96	20.84	23.19	1930.50	1716.00	Throat swab	P	P	P
15	34.37	34.38	21.70	23.10	2216.50	1144.00	Throat swab	P	P	P
16	—	—	—	38.56	—	—	Throat swab	N	N	N
17	34.33	34.27	22.08	20.28	1215.50	2502.50	Throat swab	P	P	P
18 <sup>a</sup>	—	40.21	28.67	26.88	300.30	786.50	Throat swab	N	P	S
19	29.29	29.42	18.21	18.77	31460	42900	sputum	P	P	P
20	—	—	36.11	—	572.00	1787.50	sputum	N	N	P
21	29.89	29.25	18.30	19.36	13799	30530	sputum	P	P	P

22	30.45	29.82	21.82	23.99	—	—	sputum	P	P	N
23	26.79	26.94	15.78	17.50	23595.0	14657.50	sputum	P	P	P
24 <sup>a</sup>	40.81	—	35.98	36.21	—	1430.0	sputum	N	N	N
25 <sup>a</sup>	40.21	—	27.88	25.63	643.50	1215.50	sputum	N	P	P
26	31.10	30.32	22.56	21.94	9509.50	3789.50	sputum	P	P	P
27	27.85	27.45	20.67	20.34	84370.0	170170.0	sputum	P	P	P
28	29.89	28.22	22.10	21.31	643.50	—	sputum	P	P	N
29 <sup>a</sup>	—	40.22	16.62	17.08	715.0	715.0	blood	N	P	P
30	—	—	—	37.90	—	—	blood	N	N	N
31	35.08	34.73	21.57	22.83	500.50	715.00	Anal swab	P	P	P
32 <sup>a</sup>	—	40.55	25.20	24.68	214.50	—	Anal swab	N	P	N
33 <sup>a</sup>	—	40.06	24.00	25.68	—	250.25	Anal swab	N	P	N
34	—	—	26.66	27.22	307.45	—	Anal swab	N	P	N

436 a: one or two of the target genes had a Ct value happen to fall in the gray zone (Ct  
437 value: 37-40), and samples were retested by qRT-PCR. At last, these samples were  
438 considered as negative with Ct value>40 (both targets genes) by qRT-PCR.

439 P, positive; N, Negative; S, suspect; GGO, ground glass opacities image.

440

441 **TABLE 6 Reports summary of qRT-PCR, N-PCR and ddPCR for 34 clinical**  
442 **samples**

	qRT-PCR	OSN-qRT-PCR	ddPCR
	20 P	28 P	21P
34			
Samples	14 N	6 N	2 S

---

443 P, positive; N, Negative; S, suspect;

444

445 **TABLE 7 Comparison of the positive rate of SARS-CoV-2 nucleic results from**  
446 **different specimen types from same patient at same time.**

---

	qRT-PCR	OSN-qRT-PCR	ddPCR
Throat swab	50%	70%	50%
(n=10)	(5/10)	(7/10)	(5/10)
Sputum	70%	80%	70%
(n=10)	(7/10)	(8/10)	(7/10)

---

447

448 **Figure legends**

449 **Fig 1 Linear relationship of qRT-PCR, OSN-qRT-PCR and ddPCR for**  
450 **quantifying SARS-CoV-2 pseudoviral RNA standards for *ORF1ab* and *N* gene**

451 A. B: Expected values (converted to  $\log^{10}$ ) were plotted on the X axis versus

452 measured values of qRT-PCR (converted to  $\log^{10}$ ) on the Y axis targeting (A) *ORF1ab*

453 and (B) *N*

454 C. D: Expected values(converted to  $\log^{10}$ ) were plotted on the X axis versus measured

455 Ct values of OSN-qRT-PCR on the Y axis targeting (C) *ORF1ab* and (D) *N*.

456 E. F: Expected values(converted to  $\log^{10}$ ) were plotted on the X axis versus measured

457 values (converted to  $\log^{10}$ ) of ddPCR on the Y axis using Graph Pad Prism targeting

458 (C) *ORF1ab* and (D) *N*.

459

460 **Fig 2 The correlation analysis between OSN-qRT-PCR and ddPCR with**  
461 **qRT-PCR for quantifying SARS-CoV-2 pseudoviral RNA standards for *ORF1ab***  
462 **and *N* gene.**

463 A. B: the CT values of qRT-PCR of *ORF1ab* (A) and *N gene* (B) were plotted on the  
464 X axis versus the CT values of OSN-qRT-PCR of *ORF1ab* and *N gene* on the Y axis,  
465 the Person Correlation Coefficient between qRT-PCR and OSN-qRT-PCR for  
466 *ORF1ab* and *N gene* were 0.887 and 0.742.

467 C. D: the CT values of qRT-PCR of *ORF1ab* (C) and *N gene* (D) were plotted on the  
468 X axis versus the measured values(converted to  $\log^{10}$ ) of ddPCR of *ORF1ab* and *N*  
469 *gene* on the Y axis, the Person Correlation Coefficient between qRT-PCR and ddPCR  
470 for *ORF1ab* and *N gene* were -0.924 and -0.844.

471

472 **Fig 3 Probit analysis sigmoid curve reporting the LoD of each assay.** Replicate  
473 reactions of *ORF1ab* (A) and *N gene* (B) of qRT-PCR, *ORF1ab* (C) and *N gene* (D) of  
474 OSN-qRT-PCR and *ORF1ab* (C) and *N gene* (D) of ddPCR were done at  
475 concentrations around the detection end point determined in preliminary dilution  
476 experiments. The X axis shows expected concentration (copies/ml). The Y axis shows  
477 fraction of positive results in all parallel reactions performed. The inner line is a  
478 probit curve (dose-response rule). The outer lines are 95% confidence interval (95%  
479 CI). Data are representative of three independent experiments with 14 replicates for  
480 each concentration.

481

482 **Fig 4 Bland–Altman plots of SARS-CoV-2 quantification by using three**  
483 **methods in patient specimens**

484 A. B: Bland–Altman plots comparing qRT-PCR and OSN-qRT-PCR assays for patient

485 specimens.







486 C. D: Bland–Altman plots comparing qRT-PCR and ddPCR assays for patient  
487 specimens.





488 Notes: Blue lines indicate mean difference, Red lines indicate limits of agreement  
489 (LoA).

490


491









A.




B.




C.




D.




E.




F.




A.



B.



C.



D.

